Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 19/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | RORB | Q92753 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7185610 | 0.96 | RORC (0.46) | RORCCYP2C9CYP3A4CYP2C19TYK2 | |
| SCHEMBL7186460 | 0.90 | RORC (0.41) | RORCCYP2C9CYP3A4CYP2C19TYK2 | |
| SCHEMBL7186747 | 0.88 | RORC (0.39) | RORCCYP2C9CYP3A4CYP2C19TYK2 | |
| SCHEMBL7175982 | 0.88 | RORC (0.39) | RORCCYP2C9CYP3A4CYP2C19TYK2 | |
| SCHEMBL7181387 | 0.88 | RORC (0.39) | RORCCYP2C9CYP3A4CYP2C19TYK2 | |
| SCHEMBL7180621 | 0.85 | TAS2R14 (0.38) | RORCCYP2C9CYP3A4 | |
| SCHEMBL7181426 | 0.83 | TAS2R14 (0.41) | RORCCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL7175306 | 0.83 | TAS2R14 (0.39) | RORCCYP2C9CYP3A4 | |
| SCHEMBL7183559 | 0.83 | SMN1; SMN2 (0.43) | RORCCYP2C9CYP3A4 | |
| SCHEMBL7179370 | 0.82 | TSHR (0.38) | RORCCYP2C9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | RORC 1336/4885CYP2C9 1094/4885CYP3A4 1652/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | RORC 1254/4885CYP2C9 1606/4885CYP3A4 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.